<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03914547</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00000545</org_study_id>
    <secondary_id>1R01DK118514-01A1</secondary_id>
    <nct_id>NCT03914547</nct_id>
  </id_info>
  <brief_title>Home Video-based Telemedicine to Reduce Hypoglycemia Fear in Parents of Young Children</brief_title>
  <acronym>REDCHiP</acronym>
  <official_title>Home Video-based Telemedicine to Reduce Hypoglycemia Fear in Parents of Young Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Kansas Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Children's Mercy Hospital Kansas City</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Florida</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Kansas Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigators developed REDCHiP (Reducing Emotional Distress for Childhood Hypoglycemia in
      Parents), an innovative video-based telemedicine intervention. In the pilot work,
      investigators found preliminary efficacy for REDCHiP in reducing parental FH, parenting
      stress, and children's HbA1c. The objective of this clinical trial is to conduct a randomized
      clinical trial (RCT) comparing REDCHiP to a relevant attention control intervention (ATTN) in
      families of young children, thereby continuing to establish its efficacy. The proposed R01
      aims are: 1) To evaluate whether parents who receive REDCHiP report reductions in FH and
      parenting stress at post-treatment compared to parents who receive the ATTN; 2) To evaluate
      whether children of parents who receive REDCHiP have a lower HbA1c and less glycemic
      variability at post-treatment compared to children of parents who receive ATTN; 3) To examine
      whether families who receive REDCHiP maintain reductions in FH, parenting stress, and child
      HbA1c at a 3-month followup compared to families who receive ATTN.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this trial is to examine the efficacy of a real-time video-based telemedicine
      intervention addressing parental fear of hypoglycemia (FH) in families of young children with
      type 1 diabetes (T1D). Hypoglycemia is a common negative event associated with intensive
      insulin therapy in children with T1D. Young children with T1D are particularly vulnerable to
      episodes of hypoglycemia because they tend to be more insulin sensitive, may engage in
      unpredictable eating and physical activity patterns, and may be less able to recognize and
      report symptoms. Parents and young children living with T1D quickly learn to fear
      hypoglycemia because it is uncomfortable, embarrassing, seemingly unpredictable, and
      potentially dangerous. Indeed, research shows that parents of young children report high
      rates of moderate to severe FH. Unfortunately, FH leads to two problems: impaired quality of
      life and compensatory behaviors that raise children's blood glucose levels leading to
      on-going poor metabolic control (HbA1c) and an increased risk for long-term vascular
      complications. Responding to a critical need for interventions to treat parental FH in
      families of young children, investigators developed an innovative video-based telemedicine
      intervention, called REDCHiP (Reducing Emotional Distress for Childhood Hypoglycemia in
      Parents). REDCHiP uses cognitive behavioral therapy, T1D education, and behavioral parent
      training in a 10-session individual and group-based telemedicine program, to reduce parental
      FH and to teach parents how to change hypoglycemia avoidance behaviors. In the pilot work,
      investigators found preliminary efficacy for REDCHiP in reducing parental FH, parenting
      stress, and children's HbA1c. The objective of the proposed R01 is to conduct a randomized
      clinical trial (RCT) comparing REDCHiP to a relevant attention control intervention (ATTN) in
      families of young children, thereby continuing to establish its efficacy. The proposed R01
      aims are: 1) To evaluate whether parents who receive REDCHiP report reductions in FH and
      parenting stress at post-treatment compared to parents who receive the ATTN; 2) To evaluate
      whether children of parents who receive REDCHiP have a lower HbA1c and less glycemic
      variability at post-treatment compared to children of parents who receive ATTN; 3) To examine
      whether families who receive REDCHiP maintain reductions in FH, parenting stress, and child
      HbA1c at a 3-month followup compared to families who receive ATTN. Investigators will recruit
      180 families with the goal of retaining at least 144 through the 3-month followup. After
      informed consent, investigators will randomize parents to either REDCHiP or ATTN and have
      them complete baseline measures (e.g., parent surveys, child glucose sensing, child/parent
      accelerometry, and child HbA1c). Then, parents in both groups will participate in 10
      video-based telemedicine sessions matched for time and format (group v individual). At
      post-treatment, parents and children will repeat the baseline assessment; at the 3-month
      followup, parents will complete surveys and children will undergo glucose sensing and an
      HbA1c. Primary outcomes of the revised trial are: parents' FH, parenting stress, children's
      HbA1c levels and children's glycemic variability (measured by percent time above, below and
      within-range). Secondary measures include child physical activity and sleep, parent sleep,
      parent depressive symptoms and anxiety, and parent psychopathology.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 15, 2019</start_date>
  <completion_date type="Anticipated">March 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Child Glycemic Control</measure>
    <time_frame>change from baseline to post-treatment (week 14)</time_frame>
    <description>Child glycemic control will be measured by change in hemoglobin A1c (HbA1c) NGSP (%) between baseline and post-treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Parents Hypoglycemia Fear</measure>
    <time_frame>change from baseline to post-treatment (week 14)</time_frame>
    <description>Parental fear will be measured by the Hypoglycemia Fear Survey - Parents of Young Children (HFS-PYC), a 26-item survey with a score range of 26-130. Higher scores indicate a higher fear rating.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">360</enrollment>
  <condition>Type 1 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>REDCHiP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>REDCHiP uses 10- video-based telemedicine sessions to deliver T1D education, behavioral parent training, and problem-solving to enhance parents' knowledge and skills. Sessions last about 45-60 minutes each.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ATTN</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ATTN uses 10- video-based telemedicine sessions to deliver general patient education specific to young children. Similar to REDCHiP, all ATTN sessions last 45-60 minutes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>REDCHiP</intervention_name>
    <description>REDCHiP includes seven group-based sessions and three individual sessions. REDCHiP uses a three-pronged approach to reduce parents' FH. It uses T1D education and problem-solving to enhance parents' knowledge and skills. It uses child age-appropriate behavioral parent training to promote parents' skills and confidence in managing disruptive child behaviors and reducing their reliance on hypoglycemia avoidance behaviors. It uses cognitive-behavioral therapy strategies to help parents reduce maladaptive thinking/coping related to hypoglycemia fear.</description>
    <arm_group_label>REDCHiP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>ATTN</intervention_name>
    <description>Provides a similar attention control. ATTN includes seven group-based sessions and three individual sessions.</description>
    <arm_group_label>ATTN</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Child age between 2-5.99 years

          -  Type 1 diabetes diagnosis â‰¥6 months

          -  Child is on an intensive insulin regimen (pump or multiple daily injection)

        Exclusion Criteria:

          -  Parents of children on a conventional regimen

          -  Children who have an allergy or sensitivity to the adhesive and/or skin preparation
             used for continuous glucose monitoring

          -  Children with a comorbid chronic condition (e.g., renal disease)

          -  Parents who do not speak English.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>6 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susana Patton, PhD, CDE</last_name>
    <role>Principal Investigator</role>
    <affiliation>susana.patton@nemours.org</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Susana R Patton, PhD, CDE</last_name>
    <phone>904-697-3595</phone>
    <email>susana.patton@nemours.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Andrew McConville, BA</last_name>
    <email>ammcconville@cmh.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kimberly Driscoll, PhD</last_name>
      <email>k.driscoll@phhp.ufl.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Susana Patton, PhD, CDE</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Children's Mercy Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Clements, MD PhD</last_name>
      <email>maclements@cmh.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 11, 2019</study_first_submitted>
  <study_first_submitted_qc>April 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 16, 2019</study_first_posted>
  <last_update_submitted>April 2, 2020</last_update_submitted>
  <last_update_submitted_qc>April 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
    <mesh_term>Hypoglycemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>no plan to share individual participant data; de-identified group data may be available to qualified researchers upon request to the principal investigator</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

